NCT07194590View on ClinicalTrials.gov

Equol and Vascular Function in Women With Chronic Kidney Disease

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

74

Participants

Timeline

Start Date

December 1, 2025

Primary Completion Date

November 30, 2030

Study Completion Date

November 30, 2030

Conditions
Chronic Kidney Disease (Stage 3-4)Vascular FunctionCognitive FunctionsCerebrovascular FunctionBlood Pressure
Interventions
DRUG

Equol

This group will receive 10 mg equol per day (2 capsules/day, 5mg equol/capsule).

DRUG

Placebo

This group will receive 2 placebo capsules per day.

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

University of Colorado, Denver

OTHER

NCT07194590 - Equol and Vascular Function in Women With Chronic Kidney Disease | Biotech Hunter | Biotech Hunter